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Abstract
The incidence of global obesity and Type 2 diabetes has increased 
and is predicted to rise to 30% of the global population. Diet and 
lifestyle factors are incapable to resolve the increased incidence for 
obesity and diabetes in various populations of the world. Developing 
countries have come to the forefront because of the higher diabetic 
epidemic. The urbanization may possibly provide an explanation for 
the global diabetic epidemic. In Western countries the metabolic syn-
drome and non alcoholic fatty liver disease (NAFLD) have reached 
30 % of the population and now at present NAFLD afflicts 20% of 
developing populations. Western diets and sedentary lifestyles cause 
metabolic disorders in developing countries which may increase neu-
rodegenerative diseases by the disrupted metabolism of xenobiotics 
in urban populations. In developing countries access to high calorie 
diets in urban areas down regulate
liver nuclear receptors that are responsible for glucose, lipid and 
toxicological sensing and interrupt the metabolism of xenobiotics that 
become toxic to various tissues such as the pancreas, heart, kidney, 
brain and liver. Xenobiotics in urban areas induce epigenetic changes 
that involve chromatin remodelling by alterations in transcriptional 
regulators with modification of histones. Dysfunction of nuclear re-
ceptors such as the calorie sensitive sirtuin 1 (Sirt 1) gene involves 
abnormal nutrient metabolism with insulin resistance, NAFLD, en-
ergy balance and circadian rhythm disorders. In obesity and diabetes 
insulin resistance has been connected to poor xenobiotic metabolism
with the toxic affects of increased xenobiotic transport to the 
brain associated with neurodegeneration. Dietary interventions to 
increase xenobiotic metabolism are likely to reduce oxidative stress 
and neuroendocrine disease in developing countries. Prevention pro-
grams are an important goal of international health organizations and 
in developing countries the plans to adapt a healthy diet, active life-
style and reduced exposure to xenobiotics are important to manage 
the global epidemic for obesity and diabetes.
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Introduction 
Developing countries are important to the understanding of dis-
ease processes related to the molecular basis of cell dysfunction and 
these populations can be used to test the hypothesis of the origins and 
cause of the metabolic syndrome, accelerated obesity and cardiovas-
cular disease in Western populations. In previous studies disorders 
such as obesity and diabetes were lower in developing countries and 
were related to diet, lifestyle and exercise. In developing countries the 
rapid migration from the rural to urban areas can be used as a model 
[1,2] and may be an important factor that has accelerated the glob-
al diabetic epidemic which has spread to developing countries. The 
global rise in obesity and severity of diabetes may allow the interpre-
tation of risk factors in developing countries that may possibly explain 
the cause of early nuclear and cellular dysfunction in Western com-
munities. Interests in the gene environment interactions that change 
gene expression that affect cellular glucose and lipid metabolism are 
of considerable interest. Diets high in calories with alcohol consump-
tion in developing countries may affect gene-environment interac-
tions. Developing countries in urban areas may differ from developed 
countries in relation not only to the calorie content of the diet but 
also the presence of specific chemicals such as xenobiotics and xeno-
metals. In developing countries (urban areas) access to high calorie 
diets may downregulate liver nuclear receptors that are responsible 
for toxicological sensing and interrupt the metabolism of xenobiotics 
which may rise in the blood plasma with transport to various cells and 
tissues such as the pancreas, heart, kidney, brain, liver and lungs. The 
relationship between the food intake and equilibration of xenobiotics 
or xenometals to various tissues has now become important to the de-
velopment of insulin resistance and may explain the rise in obesity in 
developing countries with relevance to the global diabetes epidemic 
and neurodegeneration (Figure 1) [3-5].
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Figure 1: Western diets induce the metabolic syndrome, NAFLD and disrupt xenobi-
otic metabolism.
Developing countries may now consume saturated fat similar to 
Western countries that may lead to hyperphagia, obesity and diabetes 
[3,4] being the major disorders in Western communities. In urban 
areas access to high calorie foods may possibly explain the rise (20%) 
in non alcoholic fatty liver disease (NAFLD) in developing countries 
with NAFLD as high as 30% in Western countries [6-8]. The effects of 
alterations in diets and lifestyle in developing countries possibly pro-
mote highly reactive intermediates that are toxic to the cell (nuclear 
apoptosis) with insulin resistance, abnormal liver lipid metabolism 
and the development of the metabolic syndrome in these countries. 
Epigenetic alterations in cells possibly lead to various other diseases 
such as cardiovascular disease, gall bladder disease, Parkinson’s dis-
ease (PD) and Alzheimer’s disease (AD) that are associated with se-
verity of diabetes and accelerated aging. The global obesity and dia-
betic epidemic in developing countries require special attention for 
the understanding of various molecular mechanisms that are involved 
in the induction or prevention of chronic disease manifestation.
Increased Global Obesity and Diabetes 
with the Metabolic Syndrome, NAFLD and 
Neurodegeneration 
The global metabolic syndrome that now includes the under 
developed countries indicates that the major endocrine disorder is 
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insulin resistance. The metabolic syndrome and NAFLD have affect-
ed 60% of individuals in developed and developing countries [6-8]. 
These insulin resistant individuals become hypercholesterolemic with 
hepatic insulin resistance playing a pivotal role in lipoprotein abnor-
malities. Lipoprotein metabolism is disturbed in these individuals 
with increased lipid accumulation and excess lipids that are stored 
in adipose tissue. In obese individuals the classification of obesity is 
with a body mass index that is greater than 30.0 Kg/m2. The liver and 
its disease progression (NAFLD) with poor lipid metabolism may re-
sponsible for the increased adiposity in obese individuals [9,10] and 
associated with the induction of the severity of the metabolic syn-
drome and diabetes in developing countries.
Developing countries are referred to as the countries of Africa, 
Asia, Latin America and Oceania. In developing countries by 2025 
individuals with obesity and diabetes are projected to increase to 
115 million and the diabetic epidemic will affect countries such as 
in Asia and Oceania (Samoa) [11,12]. Extensive literature search by 
the World Health Organization conducted with terms such as obesity, 
insulin resistance, the metabolic syndrome, diabetes, dyslipidemia, 
nutrition and physical activity in developing countries between 1966 
to June 2008 indicate that the improved economic situation in these 
developing countries is associated with increasing prevalence of obe-
sity and the metabolic syndrome in adults and children. The number 
of people with diabetes is projected to double in developing regions 
such as Africa, Asia, and India [12,13]. In Asia the diabetic epidemic 
has escalated and accounts for 60% of the world diabetic popula-
tion [14]. The diabetic epidemic has been associated with NAFLD in 
developing countries of Latin America, Asia, India and Africa with 
prevalence (20- 40 %) similar to developed countries [15-17]. Evi-
dence from various studies indicate that environmental factors are the 
major determinants of the increasing rates of diabetes with the de-
velopment of diabetes at a younger age in Asian populations. Rapid 
urbanization from 20 to 60% has occurred in Africa, India, China and 
Asia and possibly involved with the large global diabetic population 
in these developing countries [17-21]. Poor nutrition transition with 
7Top 10 Contributions on Genetics
www.avidscience.com
increased consumption of energy dense foods and edible oils, seden-
tary lifestyles, alcohol, polluted environments, poor physical activity 
and overcrowding possibly contribute to increased social stress that 
may be responsible for the dramatic increase in these chronic diseases 
[21-23].
Polluted environments contain chemical compounds foreign to 
animals and humans are referred to as xenobiotics that include drugs, 
drug metabolites, and environmental compounds such as pollutants 
that are not produced by the body. In the environment xenobiotics 
include synthetic pesticides, herbicides, chemicals and industrial pol-
lutants that pollute the air and water [24-26]. Global disability ad-
justed life years (DALYS) attributable to air pollution from industry in 
these developing countries is estimated to be 17 million [24]. Several 
studies show that air and water environmental pollution in develop-
ing countries especially in densely populated urban areas may con-
tribute to at least 20% of chronic diseases and possibly to deaths of 
millions of people annually in these countries. Alcohol ingestion has 
been shown to be increased in developing communities that corrupt 
xenobiotic metabolism [20]. Increased cigarette smoking (tobacco) 
allow the entry of xenometals such as heavy metals (lead, cadmium, 
manganese, iron, copper, strontium, rubidium, nickel, zinc, zirconi-
um and chromium) and chemical elements such as (sulfur, chlorine, 
potassium, calcium and bromine) into the body with toxic effects to 
the liver and brain [20].
Chronic neurodegenerative diseases associated with Type 2 dia-
betes have been shown to increase with age in developed countries 
and recent studies indicate that obesity and diabetes are associated 
with these neurodegenerative diseases especially those related to AD 
and PD [27-29]. Studies have concluded that AD is now referred to 
as Type 3 diabetes and is primarily involved with neurodegenera-
tion and insulin resistance. Neurodegenerative diseases that involve 
diabetes include ataxia-telangiectasia, Friedreich ataxia, Huntington 
disease, Prader- Willi syndrome, Werner syndrome, Wolfram syn-
drome, myotonic dystrophy and Down syndrome/trisomy 21 [29]. 
In developing countries neurodegenerative disorders such as AD, de-
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mentias, epilepsy, PD and acute ischemic stroke stand as emerging 
public health standards and are closely associated with the increased 
prevalence in obesity and the metabolic syndrome in these develop-
ing communities [28,30,31].
Gene Environment Interactions induce 
Epigenetic Alterations in Obesity and Diabe-
tes 
The gene-environment interaction in developing countries in-
dicates that urbanization facilitates increased access to food which 
leads to induction of epigenetic alterations that are associated with 
lipid and glucose dyshomeostasis as well as greater adiposity in obese 
individuals. High calorie diets regulate transcriptional responses with 
DNA modifications that include DNA methylation, histone tails, 
chromatin and micro RNA alterations that regulate DNA expression 
and promote chronic disease susceptibility. Urban environments may 
contain xenobiotics (soil, water, air) that may also contribute to epi-
genetic modifications and contribute to the global rise in obesity in 
these developing countries [32-41].
The alterations in glucose and lipid metabolism in obese individ-
uals involve nuclear receptor dysfunction that promotes liver disease 
[42-46]. Altered glucose and lipid metabolism in obesity are associ-
ated with liver nuclear receptor dysfunction with an increase in lipid 
storage in adipose tissue. Alterations in the transcriptional regulation 
of nuclear receptors are responsible for changes in energy and glu-
cose metabolism and involve the peroxisome proliferator-activated 
receptor gamma (PPAR gamma) and PPARalpha, beta/delta that are 
responsible for fatty acid, triglyceride, and lipoprotein metabolism 
[47]. The liver X receptors (LXR)/ liver receptor homolog-1 (LRH-1) 
is responsible for reverse cholesterol transport, cholesterol absorption 
and bile acid metabolism regulated by the farnesol X receptor (FXR), 
LXRs, and LRH-1 receptors. Pregnane X receptor (PXR) and the con-
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stitutive androstane receptor (CAR) have endobiotic functions that 
impact on glucose and lipid metabolism with affects on the metabolic 
syndrome associated with the pathogenesis of metabolic diseases [48-
51]. The nuclear receptor aryl hydrocarbon receptor has also been 
closely associated with NAFLD [52]. Liver nuclear receptors such as 
PXR, CAR and xenobiotic sensing nuclear receptor (SXR) are respon-
sible for the detection of foreign toxic substances (xenobiotics) and 
respond by the expression of cytochrome p 450 (CYP 450) enzymes 
involved in the defense against xenobiotics (drugs) for rapid clearance 
by the liver [53,54]. Liver nuclear receptors are involved in the metab-
olism of nutrients (glucose, fatty acid and cholesterol), bile acid and 
drug metabolism [54-58] and closely involved in the pathogenesis of 
chronic diseases such as NAFLD, obesity, diabetes, atherosclerosis, 
gall bladder disease [59-61] and neurodegeneration.
The gene environment interactions induce epigenetic changes 
involve alterations in nuclear receptors with chromatin remodelling 
that are linked to obesity and diabetes. High fat and high cholesterol 
diets interfere with nuclear receptors and chromatin remodelling that 
are linked to oxidative stress, insulin resistance and NAFLD. Interest 
in calorie restriction and transcriptional regulation of nuclear recep-
tors has increased and these receptors are closely involved with insu-
lin resistance. Dietary regulation of the nuclear receptors involves the 
calorie sensitive anti-aging gene Sirtuin 1 (Sirt 1) that is principally 
involved in obesity, liver lipid metabolism (NAFLD) and brain neu-
ronal proliferation with close links to the development of AD [61,62]. 
Sirt1 is a NAD+ dependent protein deacetylase and is involved in the 
deacetylation of the nuclear receptors (Figure 2) with its critical in-
volvement in insulin resistance [63,64].
10 www.avidscience.com
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Figure 2: Sirtuin 1 regulation of chromatin structure and gene expression with effects 
on obesity and diabetes.
Sirt 1 is involved in metabolic regulation and in the repair of 
deoxyribonucleic acid (DNA) damage with epigenetic alterations 
involving histone deacetylation in chromatin [65,66]. Sirt 1 involve-
ment in PXR activation occurs by deacetylation of the PXR liver re-
ceptor [67,68] and is linked to protection of DNA by xenobiotics with 
epigenetic alterations involving histone deacetylation [69-71]. Sirt1 
maintains the DNA to prevent gene modification of various genes 
including CYP 450 enzymes [72] and allows rapid metabolism of 
xenobiotics that enter the organism. In under developed countries 
urbanization and Western diet changes involve Sirt 1dysregulation 
caused by alterations in transcriptional regulators and modification of 
chromatin that contribute to endocrine abnormalities such as insulin 
resistance, NAFLD and energy balance disorders [73-79].
Interests in calorie restriction and neurodegeneration involve 
Sirt 1 mediated deacetylation of the transcriptional factor FoxO3a that 
represses Rho-associated protein kinase-1 gene expression and acti-
vation of the non amyloidogenic α-secretase processing of the amy-
loid precursor protein (APP) with the reduction of amyloid beta (Aβ) 
generation [80]. Environmental changes with dietary consumption of 
xenobiotics affect chromatin remodelling that regulate gene expres-
sion with affects on appetite and hyperphagia that promotes obesity, 
diabetes and neurodegeneration [81,82]. Interests in transcriptional 
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factors (co-regulator complexes) modify Sirt 1chromatin interactions 
and nutrient, drug and toxin metabolism [81-83]. Environmental in-
hibitors modify Sirt1 and its regulators with modifications in chroma-
tin structure and prevent activators of Sirt1 that regulate appetite and 
food intake [84]. In developing countries movement of populations 
from rural to urban regions alter Sirt1 and nuclear receptor interac-
tions that act as metabolic and toxicological sensors that allow popu-
lations to adapt to environmental changes. High calorie diets down 
regulate nuclear Sirt 1 activity disrupted xenobiotic or xenometal me-
tabolism that alters gene expression with the acceleration in aging and 
the development of obesity and diabetes in these populations.
Metabolic Disorders Affect the Metabo-
lism of Xenobiotics and Increase the Concen-
tration of Neurotoxins
Major threats of xenobiotics such as environmental pollut-
ants (Figure 3) may increase with age in individuals from develop-
ing countries [85-89]. These xenobiotics allow induction of various 
chronic illnesses such as obesity and diabetes by alteration in liver 
and brain function. The global obesity epidemic (30%) now includes 
the developing countries (20%) and is possibly connected to the large 
diabetic population in developing countries with unhealthy diets and 
poor liver xenobiotic metabolism involved in the severity of diabetes 
[90-94]. In obesity and diabetes the liver and brain have been found 
to be diseased with insulin resistance connected to the peripheral 
organ disease progression [84]. Obese and diabetic individuals have 
blood brain barrier (BBB) disorders [95] and loss of BBB trafficking 
of chemicals, xenobiotics or xenometals [96-98] to the brain may 
increase the risk of neuronal apoptosis with the promotion of neu-
roendocrine disease and the increased risk for PD in these individu-
als [96,97-99]. Association between xenobiotics and insulin resistance 
adds support to the affects of xenobiotics on their receptors CYP 450 
in liver and brain cells of obese and diabetic individuals [100-104].
12 www.avidscience.com
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Figure 3: Nuclear receptors control xenobiotic metabolism with effects on DNA 
modification and neuron apoptosis.
In experimental animals high fat diets were closely associated 
with disturbances in the suprachiasmatic nucleus and appetite con-
trol with the abnormal involvement of Sirt1 in the central control of 
circadian rhythms [105-111]. Sirt 1’s abnormal involvement in food 
intake and appetite regulation has been associated with the risk for 
obesity [107,110,111]. The clearance, metabolism and elimination of 
xenobiotics are controlled by nuclear receptors (Sirt1/PXR) and the 
circadian regulation of CYP450 enzymes that are involved in xeno-
biotic and nutrient metabolism [49,112-114]. High calorie diets with 
lifestyle alterations after relocation to urban areas possibly delays the 
metabolism of xenobiotics with induction of cardiovascular disease 
[115-121] metabolic diseases such as obesity and diabetes [11,122] 
and relevance to drug induced Parkinsonian and neurodegeneration 
in these countries [123-125].
Accelerated neurodegeneration such as in PD and AD is con-
nected to the diabetic global epidemic with insulin resistance and ab-
normal peripheral glucose and lipid metabolism. Excess xenobiotics 
(CNS drugs, CAD drugs, anti-cancer drugs, antimicrobial, antiviral, 
13
Top 10 Contributions on Genetics
www.avidscience.com
compounds) are possibly involved in the molecular mechanisms of 
neuroendocrine disease that is linked to diabetes, PD and AD. Or-
ganic pollutants in the environment are higher in developing coun-
tries and the half life of xenobiotics by poor hepatic metabolism is 
decreased with the increase in NAFLD (20%) and diabetes associated 
with these under developed countries (Figure 3). Loss of hepatic cho-
lesterol metabolism as associated with NAFLD is closely connected to 
poor liver Aβ homeostasis with consequences to severe neurodegen-
eration such as PD and AD. In 60% of individuals in global popula-
tions (developed and developing countries) the peripheral sink Aβ 
hypothesis is absent since NAFLD has increased to nearly half of the 
world population and ill affects of poor xenobiotic and hepatic Aβ 
metabolism correlated with toxic affects to various tissues such as the 
heart and brain [61,62].
Interests in xenobiotic metabolism have escalated recently since 
xenobiotics are involved in the generation of reactive intermediates 
that corrupt DNA repair and promote DNA modifications [126-128]. 
Xenobiotics release reactive electrophiles that are possibly connected 
to nuclear aggregation and endoplasmic reticulum (ER) stress [129] 
with protein deposits in cells (Figure 4). The damage to DNA occur-
ring in neuronal cells with xenobiotics is with the formation of DNA 
adducts, DNA strand breakage and altered DNA function [127,130]. 
Sirt 1 is closely involved in with chromatin modification and protec-
tion of neurons from genotoxic stress with the involvement of DNA 
repair enzymes and repair of double strand breaks in damaged chro-
matin structure [131,132]. In liver and brain cells with low Sirt 1 
activity electrophiles from xenobiotic metabolism react with micro 
ribonucleic acid (RNA) [133-135] or by covalent binding to nucleo-
phillic centres in cellular protein and DNA [136-139]. Adduct forma-
tion disrupts DNA or protein structure with damage to the nucleus 
and various subcellular organelles [128,130,140] such as the ER and 
mitochondria with metabolic alterations. Diets that disrupt Sirt 1’s 
protection of ER stress are also implicated in mitochondrial dysfunc-
tion with the essential role of Sirt 1 and nuclear receptors in the main-
tenance of the mitochondria and their biogenesis [140-143]. Xenobi-
14 www.avidscience.com
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otics promote oxidative stress with the release of radicals that cause 
chain reactions with the attack on DNA, lipids, proteins and carbohy-
drates. Xenobiotics generate electrophilic intermediates that involve 
abnormal protein folding as assessed by quality control mechanisms 
such as the unfolded protein response and the deposition of unfolded 
proteins in the ER. As nutrient levels rise Sirt 1 activity falls and xeno-
biotic oxidative processes rise with protein misfolding connected with 
insulin resistance in neurodegenerative diseases such as PD and AD.
Figure 4: The effects of xenobiotics on nuclear apoptosis and ER stress in obesity and 
diabetes.
Unhealthy Diet, Drugs and Lifestyle In-
duce Chronic Disease and Neurodegenera-
tion 
Populations that consume alcohol and tobacco such as that in 
developing countries may inhibit hepatic nuclear receptors with al-
terations in metabolic regulation of cholesterol, fatty acids, glucose 
and toxic chemicals. Alcohol is a Sirt1 inhibitor [144-147] and its con-
sumption may promote hepatic dysfunction such as alcoholic fatty 
liver with the ill affects on hepatic xenobiotic metabolism that are 
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now released to various organs in the periphery and brain. Activa-
tors of hepatic Sirt 1 are important to prevent chronic diseases with 
the maintenance of liver nuclear receptors and regulation of nutrient 
and xenobiotic metabolism [61,62] Foods that contain toxic xenobi-
otics [148] induce genotoxic stress with chromatin modifications that 
leads to hepatic DNA damage and NAFLD that threaten the survival 
of various obese and diabetic individuals [148,149].
Interest in fat consumption (low or high) may require further 
evaluation and may contain lipophillic xenobiotics. Lipophillic xeno-
biotics [150,151] such as aldrin and dieldrin may rapidly transport 
across membranes to various cells and tissues may not be processed 
by the liver. Gene-environment interactions that lead to changes in 
diet and appetite affect peripheral gene expression with the devel-
opment of the metabolic syndrome and possibly involve the excess 
consumption of lipophillic xenobiotics found in fat (milk) that are 
toxic to the neurons in the central nervous system. Rapid xenobiotic 
metabolism is triggered by low calorie diets and poor nutrition leads 
to abnormal xenobiotic metabolism with significant affects on DNA 
strand breakage with cell apoptosis. Compounds such as reservatrol 
(Sirt1 activator) are essential to maintain the DNA repair [152-154] 
and are involved in inhibition of CYP450 enzymes required for xeno-
biotic metabolism [155,156].
In developing countries higher environmental organic pollutants 
can enter the water supply and foods such as vegetables, rice, fruits, 
meat and dairy products. Consumption of water and food may release 
xenobiotics that may alter cellular DNA and RNA related to the epi-
genetic changes in metabolic diseases and neurodegeneration (Figure 
5). Food monitoring for xenobiotics and xenometals has become of 
central interest to prevent chronic diseases and acceleration of aging 
with the prevention of ingestion of toxic chemicals, xenobiotics and 
organic pollutants (88-90). In Western communities nutritional diets 
are of importance to prevent NAFLD and improve hepatic xenobi-
otic metabolism in these communities. Xenobiotics and its connec-
tions with various chronic diseases may involve abnormal xenobiotic 
biotransformation and their reactions such as oxidation, conjugation 
16 www.avidscience.com
Top 10 Contributions on Genetics
and reduction are important to its rapid metabolism and excretion 
in bile and urine. Chronic diseases such as gall bladder disease and 
hypothyroidism has increased with the metabolic syndrome and gall 
bladder removal now closely related to NAFLD [157,158]. The slow 
metabolism of xenobiotics in individuals with insulin resistance [159] 
may lead to dysfunction of the thyroid and hypothyroidism is now 
involved with the progression to obesity and diabetes [160-162].
Figure 5: Nutritional diets and active lifestyle improve xenobiotic metabolism and 
reduce chronic diseases such as obesity, diabetes and neurodegenration in developing 
countries.
Anti-obese drug therapy in obese individuals may be more use-
ful and successful with consumption of selected foods that are very 
low in xenobiotics, chemicals or xenometals that allowing the the liver 
to rapidly clear these toxic compounds from the periphery before en-
tering the brain (Figure 5). Anti-steatotic diets and drug treatment 
may accelerate clearance of liver xenobiotics by improving insulin 
resistance and expression of CYP450 expression [102-104] in obese 
or diabetic individuals. Other behavioural factors such as stress and 
anxiety that affect the circadian rhythm that regulates xenobiotic me-
tabolism have become important to various communities. Nutritional 
diets (plant versus meat) are designed to maintain the toxicological 
processing of xenobiotics with the critical role of liver xenobiotic en-
zymes (CYP450) in their metabolism. Micronutrients, minerals and 
vitamins such as nicotinamide, riboflavain, niacin, folic acid, vitamin 
17
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E, vitamin A are essential for xenobiotic metabolism [113]. Diets that 
contain appropriate protein quality, carbohydrate and lipid (polyun-
saturated) content are essential for xenobiotic metabolism and nutri-
tional deficiency has been closely related to poor xenobiotic metabo-
lism.
Conclusion 
In various regions in developed and underdeveloped countries 
the incidence of overweight and obesity has been closely connected 
to the diabetic epidemic. Urbanization in developing countries may 
possibly provide an explanation for the global diabetic epidemic. The 
obesity and diabetic epidemic in developing countries require urgent 
attention to maintain cellular DNA and RNA and reverse epigenetic 
changes induced by diet and xenobiotics that accelerate insulin resist-
ance, cardiovascular disease and neurodegeneration. Severity of the 
world wide diabetic epidemic may be controlled by consumption of 
low calorie nutritional diets that are designed to maintain liver glu-
cose, lipid and xenobiotic metabolism and prevent genotoxic stress 
that is associated with the increase in the diabetic epidemic and neu-
rodegeneration in developing countries.
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